#United States #Los Angeles #UCB #Epilepsy #FINTEPLA

UCB's Groundbreaking Research on Epilepsy at AES 2024

At the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, UCB presented a wealth of new data focusing on the challenges and burdens faced by individuals living with epilepsy and their caregivers. These findings are crucial as they shed light on specific needs and solutions that could significantly enhance the management of epilepsy and related conditions.

Women's Perspectives on Epilepsy Management

A prominent highlight of UCB's presentation was a social media listening study focusing on women of childbearing age (WoCBA) with epilepsy. Conducted over a year, this study analyzed nearly 250,000 social media posts from platforms like X, YouTube, and Instagram across six countries, including the U.S., UK, France, Germany, Spain, and Italy. The study revealed that these women often struggle to access timely and relevant information regarding their treatment options during key stages of their motherhood journey.

Conflicting guidance, combined with unanswered questions about managing epilepsy and pregnancy, contributes to anxiety and confusion among WoCBA. UCB emphasized the importance of empowering these women through education and open communication, enabling them to make well-informed decisions regarding their health.

The Impact of Prolonged Seizures

Another significant aspect covered was the severe impact of prolonged seizures (PS) on both patients and their caregivers. UCB's findings indicated that 71% of participants in a study reported experiencing PS, which profoundly affects mental health. Alarmingly, 74% of these individuals exhibited signs of anxiety or depression, highlighting an urgent need for comprehensive mental health support for those affected by epilepsy. UCB's research underscores the necessity for timely interventions to improve both physical and emotional well-being for patients and families dealing with epilepsy.

Innovative Solutions: Staccato® Alprazolam

UCB introduced findings related to the Staccato® alprazolam, an innovative inhalation device currently undergoing Phase 3 clinical trials for prolonged seizures. This device promises rapid and effective seizure termination by leveraging inhalation technology, which could drastically change how acute seizures are managed in outpatient settings. The potential of this treatment is significant, offering a new avenue for patients at risk of experiencing prolonged seizures, thereby addressing a critical unmet need in epilepsy care.

Quality of Life for Caregivers and Patients

Additionally, UCB shared outcomes from a quality-of-life survey targeting caregivers of individuals with developmental and epileptic encephalopathies (DEEs). The survey showed a clear perception of disruptive experiences related to seizures, sleep, communication, and other aspects of daily living. By enhancing understanding of these disruptive symptoms, researchers can prioritize interventions that would lead to improved outcomes for both patients and their caregivers.

Efficacy of FINTEPLA® in Managing Seizures

UCB also presented new efficacy data on FINTEPLA® (fenfluramine), approved for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. Results from recent trials indicated that patients previously receiving placebo saw significant improvements when transitioned to FINTEPLA, underscoring its effectiveness in managing seizure frequency and associated complications.

Commitment to Epilepsy Care

Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes at UCB, stated, "By engaging with those impacted by epilepsy, we gain invaluable insights that help us address their unique healthcare needs. The data showcased at the AES underscore our dedication to advancing holistic patient care and improving the quality of life for people living with epilepsy."

As UCB commits to addressing the ongoing challenges in epilepsy treatment, the information presented at the AES 2024 will hopefully catalyze further dialogue and research in this vital area. With a focus on education, innovative treatments, and mental health support, UCB aims to make strides toward a future where those affected by epilepsy can lead fuller and more empowered lives.